SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AVIGEN(avgn)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Pseudo Biologist who wrote (45)6/28/1997 2:41:00 PM
From: Czechsinthemail   of 228
 
PB,

Thanks for the post. I hadn't heard about the CEGE info and will check it out. I know Avigen has been able to show long term (over 15 months) expression of Epo in mice using a single injection of AAV vectors containing the Epo gene.

Any good news for CEGE using AAV should have positive spillover effect on AVGN. Their patented production method for AAV vector is a BIG advantage since it increases purity and production efficiency by a factor of about 1000X. I think it ensures they will be a primary player in AAV-based therapies or bought out by someone who wants to be.

With the stock priced so low, the risk/reward picture for this company looks excellent. AVGN's price should jump on any news, particularly concerning research partnerships or further developments of their preclinical products.

Baird
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News